AcclaimIP-ad

Match Document Document Title
9089529 Antibody formulations and methods  
Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
9040049 ADAM-15 antibodies and immunogenic peptides  
The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or...
9040046 Sodium pump antibody agonists and methods of treating heart disease using the same  
Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (β1) subunit of NKA are disclosed....
9040047 Combinations of anti ErbB antibodies for the treatment of cancer  
An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences...
9040045 Methods and device to neutralize soluble toxic agents in the brain  
Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include Aβ, and the methods, agents and devices are useful...
9040041 Modified FC molecules  
The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding...
9035026 Anti-CD16 binding molecules  
The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and...
9034325 Amino acid sequences directed against multitarget scavenger receptors and polypeptides  
The present invention relates to amino acid sequences that are directed against (as defined herein) multitarget scavenger receptors such as e.g. Lox-1, RAGE, CD36, SR-A1, SR-B1, galectin-1, as...
9034334 Protofibril selective antibodies and the use thereof  
The invention relates to an isolated antibody, or fragment thereof, having high affinity for human Aβ protofibrils. The invention further relates to compositions that include the antibody, or a...
9028823 Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies  
The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by...
9028815 Identification and engineering of antibodies with variant FC regions and methods of using same  
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region...
9028816 Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor  
The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3...
9029508 Dual variable domain immunoglobulins and uses thereof  
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
9028826 Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties  
Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune...
9023352 Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein  
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant...
9023350 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals  
A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in...
9023354 Combination therapy with MDM2 and EFGR inhibitors  
Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various...
9023358 Antibodies that bind to IL-23  
The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful...
9023353 Anti-(+)—methamphetamine monoclonal antibodies  
The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into...
9023348 Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof  
A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a...
9017675 Humanized and chimeric monoclonal antibodies to CD47  
Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating...
9017683 Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo  
It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which...
9017674 Antibodies to granulocyte-macrophage colony-stimulating factor  
The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and...
9017677 Methods of treating a disease mediated by sensitized T cells  
A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising an interleukin-6 (IL-6) antagonist, for example an antibody directed against IL-6 receptor, an antibody...
9017669 Anti-CDH3 antibodies and uses thereof  
The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an...
9011864 Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates  
Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells...
9011861 Therapeutic compositions for the treatment of dry eye disease  
Described herein are materials and methods for treating dry eye disease in a subject.
9011859 Methods for treating TWEAK-related conditions  
The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage...
9011851 Inhibitors of her3 activity  
The present invention relates to a pharmaceutical composition comprising as an active agent an inhibitor of HER3 activity, particularly an anti-HER3-antibody. Further, the use of this composition...
9011850 Method of stabilizing antibody and stabilized solution-type antibody preparation  
The present invention provides a method of suppressing the formation of a soluble association of an antibody in a solution; a method of suppressing the formation of a chemically degraded product...
9011852 Anti-C5a antibodies  
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing...
9011856 Antibodies specific for sclerostin and methods for increasing bone mineralization  
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by...
9011858 Variable region sequences of IL-31 monoclonal antibodies and methods of use  
Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules...
9005614 PRLR-specific antibody and uses thereof  
PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
9005615 Methods for treatment of inflammatory diseases  
The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment...
9005611 Protein formulation  
A composition comprises a biological molecule that is susceptible to aggregation, dimerization or hydrolysis, wherein the ionic strength is less than 40 mM.
9005620 Compounds  
Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating...
9005599 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents  
The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering...
8999331 Immunobinders directed against sclerostin  
Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for...
8999332 Regulators of MMP-9 and uses thereof  
A method of regulating an activity of metalloproteinase 9 (MMP-9) is disclosed. The method comprises contacting the MMP-9 with an agent which specifically interacts with an OG domain of the MMP-9....
8999326 Oncotherapeutic application of inhibitors of high-affinity glucose transporters  
The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject...
8999333 Human tissue factor antibody and uses thereof  
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to...
9000132 Lipoprotein-associated phospholipase A2 antibody compositions and methods of use  
The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in...
8999330 Antagonists of IL-6 to prevent or treat thrombosis  
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in...
8999328 Polypeptides and antibodies derived from chronic lymphocytic Leukemia cells and uses thereof  
Small animal models for assessing immunomodulatory effects of compounds are provided.
8999327 Antibodies against human CSF-1R and uses thereof  
The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
8999396 Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane  
The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration...
8999329 Agonist antibody to human thrombopoietin receptor  
This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The...
8999339 Methods for treating chronic obstructive pulmonary disease  
The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically...
8992913 Antagonist antibodies against GDF-8 and uses therefor  
The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are...